Diffuse somatostatin-immunoreactive D-cell hyperplasia in the stomach and duodenum

Holle, G; Spann, W; Eisenmenger, Wolfgang; Riedel, J.; Pradayrol, Lucien

doi:10.1016/0016-5085(86)90647-5

Cited by 13 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antral D-cell hyperplasia has been described in patients with duodenal ulcer disease, sometimes associated with increased D cells of the fundus (Holle et al, 1986). No dysplastic change of the endocrine cells of the antral mucosa has been described so far.…”

Section: Dysplasiamentioning

confidence: 98%

Morphological, molecular, and prognostic aspects of gastric endocrine tumors

Solcia

Rindi

Larosa

et al. 2000

Microsc. Res. Tech.

View full text Add to dashboard Cite

Section: Dysplasiamentioning

confidence: 98%

Morphological, molecular, and prognostic aspects of gastric endocrine tumors

Solcia

Rindi

Larosa

et al. 2000

Microsc. Res. Tech.

View full text Add to dashboard Cite

“…Recently, Merchant and colleagues [60] reported an association between G-cell hyperplasia and sporadic gastrinomas in a small series of 18 patients with H. pylori gastritis treated with PPIs. This observation suggests that, as in the gastric mucosa, a proliferation of G-cells may occur in the duodenum [61].…”

Section: Preneoplastic Lesions Of Gep-nens Listed By Anatomical Sitementioning

confidence: 99%

Histopathological Landscape of Precursor Lesions of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

Biancotti

Pozzo

Parente

et al. 2022

Dig Dis

View full text Add to dashboard Cite

Background. Despite the important advances in research on neuroendocrine neoplasms of the gastro-entero-pancreatic tract (GEP-NENs), their precursor lesions are much less well known. Summary. This review analyzes the pre-neoplastic neuroendocrine lesions of the gastroentro-pancreatic tract, by adopting a coherent anatomical benchmark. In particular, the settings in which neuroendocrine precursor lesions represent well recognized pathophysiological and morphological entities (with eventual molecular correlates) have been distinguished from the ones in which the nature of preneoplastic changes is still obscure. Key Messages. The aim of the paper is to summarize what is known about precursor lesions of gastroenteropancreatic neuroendocrine tumors, with the goal of providing a useful tool for future research aimed at obtaining a fuller understanding of the underlying biology and early development of these diseases.

show abstract

“…Gastroduodenal D-cell hyperplasia Recently, diffuse, somatostatin-immunoreactive D-cell hyperplasia in the stomach and duodenum has been reported in a patient with clinical signs of dwarfism, obesity, dryness of the mouth, and goitre (Holle et al 1986). The density of the distribution of D-cells was increased between 23and 39-fold in comparison with normal values.…”

mentioning

confidence: 99%

Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract

Lamers

1987

Acta Endocrinologica

View full text Add to dashboard Cite

Somatostatin is present in the gastrointestinal tract in appreciable amounts. The highest concentrations of the polypeptide are found in the stomach, the upper small intestine, and the pancreas. Within the gastrointestinal tract, somatostatin inhibits various functions, including endocrine and exocrine secretion, motility, blood flow, absorption, and growth. The polypeptide regulates these functions by endocrine, paracrine, neurocrine or luminal mechanisms. Abnormalities of endogenous somatostatin have been implicated in several gastrointestinal disorders, including the somatostatinoma syndrome, antroduodenal D-cell hyperplasia, peptic ulcer, obesity, and liver cirrhosis.Because of its potent inhibitory effects, somatostatin or somatostatin-analogues have been used as therapeutic agents in various clinical conditions, such as upper Schusdziarra & Schmid 1986). man. Clin Endocrinol (Oxf) 12: 269-275. Williams G, Anderson J V, Williams S J R 8c Bloom S R (1987): Clinical evaluation of SMS 201-995: longterm treatment in gut neuroendocrine tumours, effi¬ cacy of oral administration, and possible use in nontumoural inappropriate TSH hypersécrétion. Acta Endocrinol (Copenh). Suppl 286: 26-36.

show abstract

Diffuse somatostatin-immunoreactive D-cell hyperplasia in the stomach and duodenum

Cited by 13 publications

References 35 publications

Morphological, molecular, and prognostic aspects of gastric endocrine tumors

Morphological, molecular, and prognostic aspects of gastric endocrine tumors

Histopathological Landscape of Precursor Lesions of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract

Contact Info

Product

Resources

About